Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

Golimumab Achieved Primary and Major Secondary Endpoints in the Largest

Phase 3 Biologic Trial Completed to Date in Psoriatic Arthritis

BOSTON, Nov. 7 /PRNewswire/ -- Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest Phase 3 biologic study ever completed in subjects with psoriatic arthritis. Findings presented at the American College of Rheumatology (ACR) Annual Scientific Meeting showed that at week 14 of the 405-patient study in subjects with active psoriatic arthritis, 51 percent of patients receiving golimumab 50 mg and 45 percent of patients receiving golimumab 100 mg experienced at least 20 percent improvement in arthritis signs and symptoms (ACR 20) compared with 9 percent of patients receiving placebo (P < 0.001 for both comparisons). Golimumab-treated patients maintained significant improvements in arthritis through week 24 and also showed substantial and sustained improvements in skin and nail psoriatic disease (as measured by a 75 percent reduction in Psoriasis Area and Severity Index [PASI 75] in patients with baseline body surface area with psoriasis of at least three percent, and the Nail Psoriasis Severity Index [NAPSI]).

Golimumab, Centocor Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as a monthly SC injection and an every twelve-week intravenous (IV) infusion (approximately 30-minutes) therapy.

"The availability of treatments that target TNF-alpha have dramatically changed rheumatologists' ap
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014  CryoLife, Inc. (NYSE: CRY ... focused on cardiac and vascular surgery, announced today that ... Executive Officer, has been elected to the Company,s Board ... Steven G. Anderson , Executive Chairman of CryoLife, stated, "Since ... be an excellent leader who is well positioned to ...
(Date:10/22/2014)... UNION CITY, Calif., Oct. 21, 2014 Abaxis, ... company manufacturing point-of-care blood analysis systems, today reported financial ... 2014. Second quarter overview: , Revenues ... quarter. , Diluted EPS of $0.24, up 33% ... , Service revenues from Abaxis Veterinary Reference Laboratories ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
... Potential for Correcting Devastating Genetic Diseases -, PHILADELPHIA, ... brain well connected to other areas, researchers successfully,delivered a ... injection of,gene therapy. If these results in animals can ... for gene therapy to treat a host of,rare but ...
... development program will examine HZT-501 as a ... mild to moderate pain -, PALO ALTO, ... held biopharmaceutical company, today announced that it has,initiated ... of its lead,product candidate HZT-501, an investigational prescription ...
Cached Medicine Technology:One Shot of Gene Therapy Spreads Through Brain in Animal Study 2One Shot of Gene Therapy Spreads Through Brain in Animal Study 3Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501 2Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501 3
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare ... location of Shriners Hospitals for Children - Lexington from ... University of Kentucky Albert B. Chandler Hospital. The new ... and operated by Shriners Hospitals for Children, and designed ... their families well into the future. , “The quality ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... and length may be showing a genetic propensity for obesity ... genes have been linked to increased body fat, but the ... lean muscle, the researchers said. At 1 year, kids ... 2 and 3, however, these genes were linked to excessive ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... , ... ... ... ...
... The presence of certain proteins in premalignant oral ... of Georgia researchers said. SIBLINGs, or Small ... five proteins that help mineralize bone but can ... cancers including breast, lung, colon and prostate. ...
... with collaborators from Life Technologies are reporting on the application ... tumors. Their findings from a proof-of-principle study on oral carcinomas ... the online science journal. VIDEO ALERT: Additional ... available on the Mayo Clinic News Blog To explore ...
... hereditary condition that leads to severe physical and mental deterioration, ... treatments to slow down or stop it. HD sufferers ... symptoms until late in life. In a new study ... and Fabiola Ribeiro of Robarts Research Institute at The University ...
... ... presented at WebInno25 , ... New York, NY (PRWEB) February 23, 2010 -- Vizibility Inc. ( www.vizibility.com ... branding service for career professionals at Web Innovators Group (aka WebInno) in Boston. Hosted ...
... ... Weight Loss. However, One-Ingredient Products May Not Work. , ... Houston, TX – February 23, 2010 – Recent studies ... cannot control their dietary urges, such as carbohydrate cravings. Could we lose weight by ...
Cached Medicine News:Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 2Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 3Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 4Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 5Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 6Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 7Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 8Health News:Elsevier's new Custom Publication Guidelines set new Standards for Publishing Pharma-Sponsored Content 9Health News:SIBLING proteins may predict oral cancer 2Health News:Mayo oral cancer study shows full tumor genome 2Health News:Protecting the brain from of a deadly genetic disease 2Health News:Vizibility A Side Dish At Web Innovators Group Event 2Health News:Vizibility A Side Dish At Web Innovators Group Event 3Health News:Sleep More, Lose Weight &#8211; Sleeplessness Linked to Obesity 2Health News:Sleep More, Lose Weight &#8211; Sleeplessness Linked to Obesity 3Health News:Sleep More, Lose Weight &#8211; Sleeplessness Linked to Obesity 4
... Certified PCR agarose is recommended for ... high-strength agarose forms gels that are easy ... high gel percentages, which minimizes the risk ... unlike genetic quality tested (GQT) products with ...
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
... PK7200 works on patented microplate agglutination ... testing system for donor ABO/Rh testing. PK7200 ... syphilis and cytomegalovirus antibody detection. The Automated ... along with the proven reliability that for ...
... Tecan Haemotyper is an ... immunohaematology. The Tecan Haemotyper combines ... (RSP) platform with the DiaMed ... to process DiaMed-ID cards and ...
Medicine Products: